4 news items
Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
ATOS
15 Apr 24
chemotherapy is expected to provide little or no benefit. These patients have substantial risk for recurrence, often after five years, and need novel
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
ATOS
9 Apr 24
and inadequate compliance, which compromises efficacy and increases the risk of mortality. Clinical benefit across treatment arms will be measured
Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
ATOS
1 Apr 24
to be sensitive to endocrine therapy but for whom chemotherapy is expected to provide little or no benefit. Full enrollment was achieved in February
Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
ATOS
22 Feb 24
management, greater access to clinical trial matching, and greater benefit to patients, providers, and researchers. Our goal is to improve and save
- Prev
- 1
- Next